PD 166285

PD 166285

CAT N°: 26804
Price:

From 55.00 46.75

PD 166285 is a tyrosine kinase inhibitor.{63262} It inhibits Src, FGFR1, EGFR, and PDGFR? (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM).{63262,63263} PD 166285 inhibits PDGF- or EGF-induced receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively).{63262} It also inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM). PD 166285 inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells.{63263} In vivo, PD 166285 (1, 5, and 10 mg/kg) inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with photodynamic therapy (PDT).{63264}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one, dihydrochloride
  • Correlated keywords
    • 193098-89-4 185039-89-8 PD166285 FGFR-1 PDGFR-? WEE-1 A-431 Sf-9 HT29
  • Product Overview:
    PD 166285 is a tyrosine kinase inhibitor.{63262} It inhibits Src, FGFR1, EGFR, and PDGFR? (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM).{63262,63263} PD 166285 inhibits PDGF- or EGF-induced receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively).{63262} It also inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM). PD 166285 inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells.{63263} In vivo, PD 166285 (1, 5, and 10 mg/kg) inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with photodynamic therapy (PDT).{63264}

We also advise you